Siemens Healthineers AG February 19 announced that the European Commission concluded its review of the planned merger with Varian Medical Systems, Inc. and approved the transaction subject to certain conditions, as it was informed in the press release of the company.
In accordance with its commitments, the company will continue to keep its imaging and oncology software solutions interoperable with third-party offerings in the future. This concerns the connection of imaging solutions for radiation therapy with third-party oncology software solutions as well as respiratory motion devices.
The closing of the transaction remains subject to receipt of regulatory approvals in other countries and satisfaction of certain other customary closing conditions.
Siemens Healthineers still expects to close the merger with Varian in the first half of calendar year 2021.
Varian is a world leader in the field of cancer care, with innovative solutions especially in radiation oncology and related software. With a holistic approach to cancer care, the company is increasingly leveraging technologies such as artificial intelligence, machine learning and data analysis to further improve cancer treatment and expand access to care.
Siemens Healthineers AG (listed in Frankfurt, Germany) is a leading medical technology company headquartered in Erlangen, German. The Company is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers, which has approximately 54,000 employees worldwide, generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion.
